1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 19,000 | 20,200 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ASCENTAGE-B (06855): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026 | - | HKEx | ||
| Do | ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Do | ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - PROPOSED GRANTS UNDER THE 2022 RSU SCHEME AND POST-IPO SHARE OPTION SCHEME TO DR. YANG AND DR. ZHAI; AND ... | - | HKEx | ||
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| Mi | ASCENTAGE-B (06855): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026 | 2 | HKEx | ||
| Mi | ASCENTAGE-B (06855): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| Mi | ASCENTAGE-B (06855): PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED ... | 3 | HKEx | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| Di | ASCENTAGE-B (06855): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| Di | ASCENTAGE-B (06855): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 24.04. | Truist reiterates Ascentage Pharma stock rating on pipeline progress | 4 | Investing.com | ||
| 24.04. | Deutsche Bank stuft Ascentage Pharma mit "Buy" ein und sieht erhebliches Kurspotenzial | 3 | Investing.com Deutsch | ||
| 24.04. | Deutsche Bank initiates Ascentage Pharma stock with buy rating | 1 | Investing.com | ||
| 22.04. | Ascentage Pharma-B Multiple Studies Selected for 2026 ASCO | 3 | AASTOCKS | ||
| 22.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 22.04. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM MULTIPLE TRIALS AT 2026 ASCO ANNUAL MEETING, INCLUDING THREE RAPID ... | 1 | HKEx | ||
| 21.04. | JPM Cuts Ascentage Pharma TP to HKD89, Maintains Overweight | 1 | AASTOCKS | ||
| 20.04. | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME | 1 | HKEx | ||
| 20.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.04. | Ascentage Pharma to Present Four Preclinical Advances at AACR 2026 in Poster Sessions | 1 | AASTOCKS | ||
| 20.04. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | 3 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 1,790 | +1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| SAREPTA THERAPEUTICS | 17,960 | +0,90 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,152 | -0,86 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 57,10 | -3,87 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| TELIX PHARMACEUTICALS | 9,300 | -0,90 % | Telix Pharmaceuticals Limited: TLX101-Px (Pixlumi) MAA Accepted in Europe | MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,757 | -1,05 % | EQS-Media: Attraktive Chance-Risiko-Konstellation? Onco-Innovations gibt erfolgreiches Scale-up bekannt | EQS-Media / 29.04.2026 / 12:18 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gab unter Bezugnahme auf seine Pressemitteilung vom 21. April 2026... ► Artikel lesen | |
| TWIST BIOSCIENCE | 51,22 | +2,95 % | Twist Bioscience Q2 2026 Earnings Preview | ||
| REPLIGEN | 96,98 | -3,79 % | Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1 | ||
| UNIQURE | 16,640 | -2,12 % | uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease | ~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential... ► Artikel lesen | |
| PHARMAMAR | 96,45 | +0,36 % | PHARMA MAR, S.A.: The Company files first quarter 2026 financial information. |
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,89 % bei einem Aktienkurs von 18,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.